Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed antidepressants. They can ease symptoms of moderate to severe depression, are relatively safe and typically cause fewer side effects than other types of antidepressants do.
With an increase in mental illnesses, there is a rising need for effective neurological drugs. Among the various neurological drugs available in the market, SSRIs drugs have high therapeutic efficacy. As a result, the number of vendors manufacturing these drugs is increasing. Moreover, health insurance companies, with support from governments, have started covering treatment expenses related to mental disorder. The rising prevalence of mental illnesses will significantly contribute to the selective serotonin reuptake inhibitors market growth.
In 2018, the global Selective Serotonin Reuptake Inhibitors (SSRIs) market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global Selective Serotonin Reuptake Inhibitors (SSRIs) status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Selective Serotonin Reuptake Inhibitors (SSRIs) development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
The key players covered in this study
Allergan Plc
Eli Lilly and Co.
GlaxoSmithKline Plc
H. Lundbeck AS
Pfizer Inc.
...
Market segment by Type, the product can be split into
Citalopram (Celexa)
Escitalopram (Lexapro)
Fluoxetine (Prozac)
Paroxetine (Paxil, Pexeva)
Sertraline (Zoloft)
Vilazodone (Viibryd)
Market segment by Application, split into
Depression
Anxiety and panic disorder
Other mental conditions
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Selective Serotonin Reuptake Inhibitors (SSRIs) status, future forecast, growth opportunity, key market and key players.
To present the Selective Serotonin Reuptake Inhibitors (SSRIs) development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Selective Serotonin Reuptake Inhibitors (SSRIs) are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Summary:
Get latest Market Research Reports on Selective Serotonin Reuptake Inhibitors (SSRIs). Industry analysis & Market Report on Selective Serotonin Reuptake Inhibitors (SSRIs) is a syndicated market report, published as Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size, Status and Forecast 2019-2025. It is complete Research Study and Industry Analysis of Selective Serotonin Reuptake Inhibitors (SSRIs) market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.